Related Experiment Video
Updated: Oct 31, 2025
Epithelial Cell Repopulation and Preparation of Rodent Extracellular Matrix Scaffolds for Renal Tissue Development
Published on: August 10, 2015
Cell-based regenerative medicine for renovascular disease
1Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA.
Abstract:
Renal artery stenosis (RAS) elicits the development of hypertension and post-stenotic kidney damage, which may become irresponsive to restoration of arterial patency. Rather than mere losses of blood flow or oxygen supply, irreversible intrarenal microvascular rarefaction, tubular injury, and interstitial fibrosis are now attributed to intrinsic pathways activated within the kidney, focusing attention on the kidney parenchyma as a therapeutic target. Several regenerative approaches involving the delivery of reparative cells or products have achieved kidney repair in experimental models of RAS and the delivery of mesenchymal stem/stromal cells (MSCs) has already been translated to human subjects with RAS with promising results. The ongoing development of innovative approaches in kidney disease awaits application, validation, and acceptance as routine clinical treatment to avert kidney damage in RAS.
Insights
Renal artery stenosis causes hypertension and kidney damage. Regenerative medicine, including mesenchymal stem/stromal cells (MSCs), shows promise for kidney repair in patients with renal artery stenosis.
Area of Science:
- Nephrology
- Regenerative Medicine
- Cardiovascular Research
Background:
- Renal artery stenosis (RAS) leads to hypertension and kidney damage.
- Damage involves intrarenal microvascular rarefaction, tubular injury, and fibrosis.
- Kidney parenchyma is a key therapeutic target.
Purpose of the Study:
- To review regenerative approaches for kidney repair in RAS.
- To highlight the potential of mesenchymal stem/stromal cells (MSCs) in treating RAS-induced kidney damage.
Main Methods:
- Review of experimental models and clinical studies on regenerative therapies for RAS.
- Focus on cell-based therapies, particularly MSCs.
Main Results:
- Regenerative approaches have shown success in experimental RAS models.
- MSC delivery in human subjects with RAS yielded promising results for kidney repair.
Conclusions:
- Intrinsic kidney pathways contribute to irreversible damage in RAS.
- Regenerative medicine, especially MSCs, offers a promising therapeutic avenue.
- Further validation is needed for routine clinical application in averting kidney damage.
Related Concept Videos
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
01:22iPS Cell Differentiation